Summary

Cangrelor is a rapid-acting, reversible, intravenous ADP-P2Y12 receptor antagonist with a plasma half-life of 3 to 6 minutes. The Maintenance of Platelet Inhibition With Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery [BRIDGE; NCT00767507] study results evaluated the use of cangrelor for bridging thienopyridine-treated patients to coronary artery bypass graft.